The Epitype GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.
Epitype GmbH is working according to ISO 13485 standards in research, development, production and management.
Epitype GmbH
Löbstedter Str. 41
07749 Jena
Germany
Phone: +49 (0)3641 5548500
Email: contact[at]epitype.de
Internet: www.epitype.de
Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn moreI acceptWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Datenschutz
Early detection of cervical cancer: „GynTect 2.0“- wider range of application by using a greater variety of patient samples
Press ReleasesJena, September 20th, 2016 – GynTect, a molecular diagnostic test developed by the biotech company oncgnostics, allows fast and reliable diagnostics of cervical cancer and the corresponding precancerous stages. The […]
An investment into life: we start a crowdfunding campaign via the platform Seedmatch – with prominent support!
BlogThose who have once been suspected to suffer from a severe disease know all-too-well, how long and grueling it can be to wait for further examinations that might bring clarity. […]
Oncgnostics GmbH cooperates with SAYRE Therapeutics in India
Press ReleasesBangalore/Jena, 28.04.2016 – The biotech firm oncgnostics GmbH will start distributing its molecular diagnostic test GynTect for use in cervical cancer diagnostics in an exclusive partnership with Sayre Therapeutics. GynTect […]
Greiner Bio-One starts international marketing of the cervical cancer triage test GynTect
Press ReleasesJena / Frickenhausen, January 20th, 2016 – With the start of 2016 the distribution of the cervical cancer triage test GynTect® by Greiner Bio-One has started. For this purpose the […]
oncgnostics and Greiner Bio-One Diagnostics sign Partnership Agreement
Press ReleasesFast and reliable results in cancer diagnostics: Biotech startup oncgnostics receives CE mark for cervical cancer test „GynTect“
Press ReleasesJena (Germany), September 18th, 2015 – A new test for use in cervical cancer screening is CE-IVD marked in whole Europe with immediate effect. It may quickly yield reliable test […]